Patient outcomes in longitudinal observational studies (POLOS) of rheumatoid arthritis: Determining the OMERACT core domain set.
Core domains
Delphi
OMERACT
Rheumatoid arthritis
longitudinal observational studies
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
07
09
2023
revised:
18
11
2023
accepted:
05
12
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
To define and select rheumatoid arthritis (RA)-specific core domain set for Longitudinal Observational Studies (LOS) within the Outcome Measures in Rheumatology (OMERACT) framework. A three-round online Delphi exercise, including patient research partners (PRPs) and other community partners in healthcare, was conducted. Domains scored 7-9 (i.e., critically important to include) by ≥ 70 % of participants in both groups were included. Items were consolidated in a subsequent dedicated meeting. Nineteen domains scored ≥ 70 % consensus in both groups. The focus group refined these into a list of twelve domains. The achieved consensus will inform the next steps of developing the core domain set for LOS in RA.
Identifiants
pubmed: 38118370
pii: S0049-0172(23)00185-3
doi: 10.1016/j.semarthrit.2023.152343
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152343Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DB: Speakers bureau: Janssen, UCB, MSD, Abbvie, Galapagos, Lilly. Research Grant: Novartis; LC: Participation on a Data Safety Monitoring Board or Advisory Board: Lilly, Hospital Clínico San Carlos. EULAR Chair of Advocacy; MALO: Grants: National Cancer Institute, Rheumatology Research Foundation, Duncan Family Institute for Cancer Prevention and Risk Assessment. Consulting fees: American Cancer Society; MdW: Speakers bureau: UCB. Convenor EULAR study group for collaborative research; VS: Founding member of the executive committee of OMERACT [1992 – present]; DBB: Support for attending meetings: Erna Hamilton Foundation. Grants: PhD Scholarships from Odense University Hospital and from the Faculty of Health Sciences; Peter Böhm: Support for attending meetings and/or travel: EULAR, FOREUM. MSA: Consulting fees: Pfizer, Eli Lilly, Syneos Health and Celgene. The rest of the authors declare no conflicts of interest.